AC Immune (NASDAQ:ACIU) Share Price Crosses Below 50-Day Moving Average – Time to Sell?

AC Immune SA (NASDAQ:ACIU) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.71 and traded as low as $2.60. AC Immune shares last traded at $2.64, with a volume of 161,167 shares traded.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Trading Down 0.8 %

The stock has a market cap of $261.20 million, a P/E ratio of -5.74 and a beta of 1.30. The firm’s 50-day simple moving average is $2.71 and its 200 day simple moving average is $3.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in shares of AC Immune by 14.6% in the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock valued at $1,999,000 after acquiring an additional 94,191 shares in the last quarter. Northern Trust Corp bought a new position in shares of AC Immune in the fourth quarter valued at approximately $1,088,000. Dimensional Fund Advisors LP boosted its holdings in shares of AC Immune by 130.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after acquiring an additional 74,358 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of AC Immune by 9.9% in the fourth quarter. Geode Capital Management LLC now owns 64,090 shares of the company’s stock valued at $173,000 after acquiring an additional 5,794 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of AC Immune in the fourth quarter valued at approximately $118,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.